Spectrum Pharmaceuticals, Inc.

Drug approvals in South Korea fell in calendar 2023 amid the shift of COVID-19 to endemic from pandemic status, as domestic pharma firms began to shift their focus back to normalized R&D activities af

How long is too long when it comes to confirming or refuting clinical benefit of an accelerated approval drug? That question is at the heart of a US Food and Drug Administration advisory committee mee

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Citeline's Biomedtracker. Lotus Licenses Corium’s Alzh

Korean pharma firms reported mixed earnings for the second quarter ended 30 June, with sales growth led by in-house new drugs, prescription businesses and the generally strong performances of overseas